SEC Form 4 · accession 0001479290-18-000048
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
Mar 13, 2018
Accepted (ET)
Mar 15, 2018 · 8:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 13, 2018 | M | 25,867 | $8.70 | A | 98,821 | D | |
| Common Stock | Mar 13, 2018 | S | 25,867 | $34.50 | D | 72,954 | D | |
| Common StockF2 | Mar 15, 2018 | F | 1,152 | $31.65 | D | 71,802 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F3 | $8.70 | Mar 13, 2018 | M | 25,867 | A | — | May 23, 2023 | Common Stock | 25,867 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mrs. Silvernail.
- F2Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award ("RSA") for 10,000 shares. The RSA vests in three (3) equal annual installments from March 15, 2016, subject to Mrs. Silvernail's Continuous Service (as defined in the Plan) on each vesting date.
- F3The Option became fully vested as of March 18, 2017.